Figures & data
Figure 1. Post induction bone marrow evaluation consistent with complete remission and measurable residual disease negativity by flow cytometry, however it showed detectable BCR:ABL1 rearrangement in myeloid segregated FISH examination. ABL1: Spectrum orange; BCR: Spectrum green; Fusion: Yellow.
Figure 2. Treatment schema for the second case, in which mini hyper-CVD/cytarabine-methotrexate alternate with blinatumomab during induction and consolidation. The patient is currently proceeding through maintenance (red arrow) with planned cycles highlighted in blue. The patient received 16 intrathecal chemotherapies during his treatment course. We are planning to continue ponatinib (15mg) for a minimum of 5 years. mini-CVD: cyclophosphamide vincristine and dexamethasone.
Data availability
The authors declare that data supporting the findings of this study are available within the article.